A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage-Reference-Cited by-同舟云学术

A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage

Published:2015-10-29 Issue:3 Volume:5 Page:e1091146
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Dezutter-Dambuyant Colette,Durand Isabelle,Alberti Laurent,Bendriss-Vermare Nathalie,Valladeau-Guilemond Jenny,Duc Adeline,Magron Audrey,Morel Anne-Pierre,Sisirak Vanja,Rodriguez Céline,Cox David,Olive Daniel,Caux Christophe

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://tandfonline.com/doi/pdf/10.1080/2162402X.2015.1091146

Reference84 articles.

1. Mesenchymal Stromal Cells: Sensors and Switchers of Inflammation

2. Mesenchymal Stem Cell: Keystone of the Hematopoietic Stem Cell Niche and a Stepping-Stone for Regenerative Medicine

3. Multipotent mesenchymal stromal cells and the innate immune system

4. Diversity, topographic differentiation, and positional memory in human fibroblasts

5. Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elevated serum soluble programmed death ligand 1 (sPD-L1) level correlate with clinical characteristics in breast cancer patients: A study at Hospital Universiti Sains Malaysia;Cytokine;2024-10

2. Exploring the dynamics of Programmed Death-Ligand 1 in canine lymphoma: unraveling mRNA amount, surface membrane expression and plasmatic levels;Frontiers in Veterinary Science;2024-07-26

3. Advances and prospects of biomarkers for immune checkpoint inhibitors;Cell Reports Medicine;2024-07

4. Serum sPD‐1 and sPD‐L1 as predictive biomarkers for HBsAg clearance in HBeAg‐negative CHB patients undergoing IFN‐based therapy;Alimentary Pharmacology & Therapeutics;2024-06-25

5. Lysosomal degradation of PD-L1 is associated with immune-related adverse events during anti-PD-L1 immunotherapy in NSCLC patients;Frontiers in Pharmacology;2024-05-10